Key facts
- It has raised $2.0M; the latest was Merger/Acquisition in Jan 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for NeuroNOS
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroNOS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroNOS
Operator of a biopharmaceutical company intended to treat autism spectrum disorder. The company's small-molecule therapy regulates nitric oxide levels in the brain to reduce nitrosative stress and improve object memory and exploratory behaviors, enabling patients to access effective treatment for the core autism symptoms.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2023
- Employees
- 3
- Website
- neuro-nos.com/
- Ownership
- Privately Held (backing)
NeuroNOS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroNOS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroNOS in its N-PORT filings yet. We sweep new filings monthly.